$TENX
TENAX THERAPEUTICS, INC. Stock $tenx

$tenx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000165495422015030 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.420M	$1.377M	$2.640M
YoY Change	-38.17%	-47.83%	125.11%
% of Gross Profit
Research & Development	$1.135M	$1.540M	$1.162M
YoY Change	23.95%	32.51%	10.45%
% of Gross Profit
Depreciation & Amortization	$1.340K	$1.200K	$1.010K
YoY Change	24.07%	18.81%	1.0%
% of Gross Profit
Operating Expenses	$2.555M	$2.917M	$3.802M
YoY Change	-20.46%	-23.27%	70.88%
Operating Profit		$2.917M	$3.802M
YoY Change		-23.27%	70.88%
Interest Expense	$0.00	$372.00	$0.00
YoY Change
% of Operating Profit		0.01%	0.0%
Other Income/Expense, Net	$5.820K	$1.320K	$3.640K
YoY Change	-101.14%	-63.74%	-63.6%
Pretax Income	-$2.549M	-$2.917M	-$3.799M
YoY Change	-31.49%	-23.22%	71.11%
Income Tax
% Of Pretax Income
Net Earnings	-$2.549M	$2.917M	$3.799M
YoY Change	-31.49%	-23.22%	-271.08%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.25	-$110.8K	-$150.7K
COMMON SHARES
Basic Shares Outstanding	44.70M shares	25.21M shares	25.20M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.124M	$3.806M	$8.354M
YoY Change	-61.97%	-54.44%	-4.09%
Cash & Equivalents	$2.124M	$3.806M	$8.354M
Short-Term Investments			$0.00
Other Short-Term Assets	$345.9K	$707.2K	$229.2K
YoY Change	229.14%	208.61%	20.61%
Inventory
Prepaid Expenses	$738.9K	$707.2K	$229.2K
Receivables
Other Receivables
Total Short-Term Assets	$3.208M	$4.514M	$8.583M
YoY Change	-43.6%	-47.41%	-3.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.189K	$9.633K	$6.489K
YoY Change	1.14%	48.45%	-92.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$9.552K	$8.435K	$8.435K
YoY Change	13.24%	0.0%	-15.65%
Total Long-Term Assets	$196.2K	$225.4K	$328.4K
YoY Change	-35.28%	-31.35%	228.37%
TOTAL ASSETS
Total Short-Term Assets	$3.208M	$4.514M	$8.583M
Total Long-Term Assets	$196.2K	$225.4K	$328.4K
Total Assets	$3.405M	$4.739M	$8.912M
YoY Change	-43.18%	-46.82%	-0.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$448.4K	$265.4K	$776.2K
YoY Change	-47.84%	-65.81%	-26.07%
Accrued Expenses	$775.0K	$424.4K	$685.1K
YoY Change	10.04%	-38.05%	128.37%
Deferred Revenue
YoY Change
Short-Term Debt	$624.3K	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$1.848M	$689.8K	$1.461M
YoY Change	18.15%	-52.8%	5.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$64.20K	$95.35K	$211.6K
YoY Change	-65.03%	-54.94%
Total Long-Term Liabilities	$64.20K	$95.35K	$211.6K
YoY Change	-65.03%	-54.94%	0.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.848M	$689.8K	$1.461M
Total Long-Term Liabilities	$64.20K	$95.35K	$211.6K
Total Liabilities	$1.912M	$785.2K	$1.673M
YoY Change	9.41%	-53.07%	5.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$289.5M	-$287.0M	-$275.3M
YoY Change	3.97%	4.25%
Common Stock	$4.584K	$2.998K	$2.520K
YoY Change	81.83%	18.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.493M	$3.954M	$7.239M
YoY Change
Total Liabilities & Shareholders Equity	$3.405M	$4.739M	$8.912M
YoY Change	-43.18%	-46.82%	-0.98%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$2.549M	$2.917M	$3.799M
YoY Change	-31.49%	-23.22%	-271.08%
Depreciation, Depletion And Amortization	$1.340K	$1.200K	$1.010K
YoY Change	24.07%	18.81%	1.0%
Cash From Operating Activities	-$2.313M	-$3.331M	-$3.022M
YoY Change	-16.45%	10.24%	26.42%
INVESTING ACTIVITIES
Capital Expenditures	-$4.000K	$0.00	-$1.670K
YoY Change	135.29%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$513.2K
YoY Change		-100.0%	5032.2%
Cash From Investing Activities	$4.000K	$0.00	$511.5K
YoY Change	-335.29%	-100.0%	5015.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	626.4K	-91.88K	9.193M
YoY Change		-101.0%	40.78%
NET CHANGE
Cash From Operating Activities	-2.313M	-3.331M	-3.022M
Cash From Investing Activities	4.000K	0.000	511.5K
Cash From Financing Activities	626.4K	-91.88K	9.193M
Net Change In Cash	-1.683M	-3.423M	6.683M
YoY Change	-39.26%	-151.22%	61.03%
FREE CASH FLOW
Cash From Operating Activities	-$2.313M	-$3.331M	-$3.022M
Capital Expenditures	-$4.000K	$0.00	-$1.670K
Free Cash Flow	-$2.309M	-$3.331M	-$3.020M
YoY Change	-16.54%	10.3%	26.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000034956
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Shell Company EntityShellCompany	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4818654	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25206914	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29980183	shares
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q3	tenx	Monthly Installment MonthlyInstallment	4443	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	372	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	0	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31524794	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34600
	dei	Entity Registrant Name EntityRegistrantName	TENAX THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2593535
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
	dei	City Area Code CityAreaCode	919
	dei	Local Phone Number LocalPhoneNumber	855-2100
	dei	Entity Address Address Line1 EntityAddressAddressLine1	ONE Copley Parkway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 490
	dei	Entity Address City Or Town EntityAddressCityOrTown	Morrisville
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27560
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	TENX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44696215	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3806399	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5583922	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	707194	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	105078	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	4513593	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	5689000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	207359	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	287692	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9633	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7108	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8435	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8435	usd
CY2022Q3	us-gaap	Assets Assets	4739020	usd
CY2021Q4	us-gaap	Assets Assets	5992235	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	265407	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	859638	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	424415	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	704340	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	689822	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1563978	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	95347	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	183589	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	95347	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	183589	usd
CY2022Q3	us-gaap	Liabilities Liabilities	785169	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1747567	usd
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	4818654	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29980183	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25206914	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	2998	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2521	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	290944132	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	282736332	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-286993279	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-278494185	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	3953851	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4244668	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4739020	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5992235	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1377283	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2639920	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4255454	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5284658	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1540205	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1162370	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4242565	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24231794	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	2917488	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3802290	usd
	us-gaap	Operating Expenses OperatingExpenses	8498019	usd
	us-gaap	Operating Expenses OperatingExpenses	29516452	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	2917488	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	3802290	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	8498019	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	29516452	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	372	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	4443	usd
	us-gaap	Interest Expense InterestExpense	949	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1323	usd
CY2021Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3642	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3368	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	253597	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	2916537	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	3798648	usd
	us-gaap	Net Income Loss NetIncomeLoss	8499094	usd
	us-gaap	Net Income Loss NetIncomeLoss	29263804	usd
CY2022Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0	usd
CY2021Q3	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-276	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0	usd
	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-72	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	29263732	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2916537	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3798372	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	8499094	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9699791	usd
CY2022Q3	tenx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.11
CY2021Q3	tenx	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.15
CY2022Q3	tenx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	26330085	shares
CY2021Q3	tenx	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	25201312	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	4625562	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	21582331	usd
CY2021Q1	tenx	Compensation On Options Issued CompensationOnOptionsIssued	91609	usd
CY2021Q1	tenx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	544651	usd
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-332	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-23748140	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	3095681	usd
CY2021Q2	tenx	Common Stock Issued For Convertible Preferred Stock Amount CommonStockIssuedForConvertiblePreferredStockAmount	0	usd
CY2021Q2	tenx	Compensation On Options Issued CompensationOnOptionsIssued	92339	usd
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	128	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	1471132	usd
CY2021Q3	tenx	Pre Fiunded Warrants And Warrants Sold Net Of Offering Costs PreFiundedWarrantsAndWarrantsSoldNetOfOfferingCosts	9192624	usd
CY2021Q3	tenx	Compensation On Options Issued CompensationOnOptionsIssued	373259	usd
CY2021Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	276	usd
CY2021Q3	tenx	Net Loss NetLoss	-3798648	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	7238643	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	4244668	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2721536	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1606201	usd
CY2022Q2	tenx	Pre Fiunded Warrants And Warrants Sold Net Of Offering Costs PreFiundedWarrantsAndWarrantsSoldNetOfOfferingCosts	7928591	usd
CY2022Q2	tenx	Compensation On Options Issued CompensationOnOptionsIssued	110031	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2861021	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	6783802	usd
CY2022Q3	tenx	Exercise Of Pre Funded Warrants Amount ExerciseOfPreFundedWarrantsAmount	477	usd
CY2022Q3	tenx	Compensation On Options Issued CompensationOnOptionsIssued	86109	usd
CY2022Q3	tenx	Net Loss NetLoss	-2916537	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	3953851	usd
	us-gaap	Profit Loss ProfitLoss	-8499094	usd
	us-gaap	Profit Loss ProfitLoss	-29263804	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3798	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3037	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	4443	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	949	usd
	tenx	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	80332	usd
	tenx	Amortization Of Right Of Use Asset AmortizationOfRightOfUseAsset	79115	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	247233	usd
	tenx	Issuance And Vesting Of Compensatory Stock Options And Warrants IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants	279686	usd
	tenx	Issuance And Vesting Of Compensatory Stock Options And Warrants IssuanceAndVestingOfCompensatoryStockOptionsAndWarrants	557207	usd
	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	0	usd
	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	-21582331	usd
	tenx	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	0	usd
	tenx	Amortization Of Premium On Marketable Securities AmortizationOfPremiumOnMarketableSecurities	9427	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	606559	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	146574	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8087748	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-874156	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-644311	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-88241	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-17892	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	803401	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	345540	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6323	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3554	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6323	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	454307	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	7928591	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	9192624	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	364546	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	364546	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	544651	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7928591	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9737275	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1777523	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	2103834	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5583922	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6250241	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3806399	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8354075	usd
	tenx	Noncash Addition To Right Of Use Asset Obtained From New Operating Lease Liability NoncashAdditionToRightOfUseAssetObtainedFromNewOperatingLeaseLiability	0	usd
	tenx	Noncash Addition To Right Of Use Asset Obtained From New Operating Lease Liability NoncashAdditionToRightOfUseAssetObtainedFromNewOperatingLeaseLiability	333779	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">The preparation of the accompanying unaudited condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.</p>
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	107192	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	95347	usd
	tenx	Liquidity And Capital Resources LiquidityAndCapitalResources	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On September 30, 2022, the Company had cash and cash equivalents of approximately $3.8 million. The Company used $9.7 million of cash for operating activities during the nine months ended September 30, 2022 and had stockholders’ equity of $4.0 million, versus $4.2 million on December 31, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Pending the outcome of the strategic process announced in September 2022, the Company expects to continue to incur certain expenses related to the development of imatinib for PAH and levosimendan for pulmonary hypertension. Based on its resources on September 30, 2022, the Company believes that it has sufficient capital to fund its planned operations through the first quarter of calendar year 2023. The Company is evaluating alternative strategic paths focused on maximizing stockholder value including, among other things, a sale, merger, or other strategic transaction. There can be no assurance, however, that this process will result in a transaction or other alternative. Pending the outcome of the strategic process announced in September 2022, the Company will need substantial additional financing in order to fund its operations beyond such period and thereafter until it can achieve profitability, if ever. The Company depends on its ability to raise additional funds through various potential sources, such as equity and debt financing, or licensing its product candidates to another pharmaceutical company. The Company intends to continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot provide assurance that it will be able to secure such additional financing on reasonable terms, or if available, that it will be sufficient to meet its needs.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">To the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to restrictive covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates or grant licenses on terms that may not be favorable to the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance.</p>
CY2022Q3	tenx	Cash And Cash Equivalents CashAndCashEquivalents	3800000	usd
CY2022Q3	tenx	Total Stockholders Equity TotalStockholdersEquity	4000000	usd
CY2021Q4	tenx	Total Stockholders Equity TotalStockholdersEquity	420000	usd
	us-gaap	Debt Instrument Term DebtInstrumentTerm	P12Y
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	183589	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	211590	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	290781	usd
	us-gaap	Depreciation Depreciation	3800	usd
	us-gaap	Depreciation Depreciation	3000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	230480	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	116243	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	107192	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	77692	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	597148	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	424415	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	704340	usd
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	364546	usd
CY2022Q3	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.0324	pure
CY2022Q3	us-gaap	Notes Payable Current NotesPayableCurrent	46124	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	372	usd
	tenx	Monthly Installment MonthlyInstallment	4443	usd
	tenx	Lease Term Period LeaseTermPeriod	P64Y
	tenx	Description Of Lease Contract DescriptionOfLeaseContract	The Company has two five-year options to extend the Lease and a one-time option to terminate the Lease 36 months after the commencement of the initial term if no additional space became available. On April 2, 2021, the Company negotiated a three-year extension to the existing lease term
	tenx	Annual Base Rent Increased AnnualBaseRentIncreased	125034	usd
	tenx	Percentage Of Annual Increase In Rent PercentageOfAnnualIncreaseInRent	0.025	pure
	tenx	Classification Of Lease Liabilities Tabletextblock ClassificationOfLeaseLiabilitiesTabletextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>September 30, 2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Current portion included in accrued liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,243</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">107,192</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Long term lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">95,347</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">183,589</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">211,590</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">290,781</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	116243	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	32047	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	129797	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	65702	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	227546	usd
CY2022Q3	tenx	Less Imputed Interest LessImputedInterest	-15956	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	211590	usd
	tenx	Remaining Lease Term RemainingLeaseTerm	P18Y
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080	pure
	us-gaap	Lease Cost LeaseCost	95719	usd
	us-gaap	Cost Maintenance CostMaintenance	1155	usd
	tenx	Common Stock Acquired CommonStockAcquired	1892905	shares
CY2022Q3	tenx	Series B Convertible Preferred Stock Conversion SeriesBConvertiblePreferredStockConversion	10232	shares
CY2022Q3	tenx	Common Stock For Conversion CommonStockForConversion	10232000	shares
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1212492	shares
	tenx	Percentage Of Preferred Stock Carries Voting Rights PercentageOfPreferredStockCarriesVotingRights	0.10	pure
	tenx	Fgdf fgdf	881.5 shares of common stock, and (ii) the right to receive up to 118.5 Holdback Shares, to be delivered 24 months after the date of issuance of the Series B Stock, subject to reduction for indemnification claims
	us-gaap	Business Combination Consideration Transferred Equity Interests Issued And Issuable BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable	3369371	usd
	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	18212960	usd
	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	21582331	usd
CY2022Q3	tenx	Accounts Payable Assumed AccountsPayableAssumed	-150000	usd
CY2022Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	-150000	usd
	tenx	In Process Research And Development Expense InProcessResearchAndDevelopmentExpense	21732331	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	21582331	usd
CY2022Q3	tenx	Conversion Of Preferred Stock Into Common Stock Maximum Ownership Limit Percentage ConversionOfPreferredStockIntoCommonStockMaximumOwnershipLimitPercentage	0.0499	pure
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29980183	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25206914	shares
CY2021Q3	tenx	Purchase Price Per Unit PurchasePricePerUnit	2.095
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20928767	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.45
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	10596027	shares
	tenx	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	0.63
	tenx	Warrants Amended And Restated WarrantsAmendedAndRestated	-9206120	shares
	tenx	Weighted Average Exercise Price Amended And Restared WeightedAverageExercisePriceAmendedAndRestared	1.72
	tenx	Warrants Amended And Restated One WarrantsAmendedAndRestatedOne	9206120	shares
	tenx	Weighted Average Exercise Price Amended And Restared One WeightedAverageExercisePriceAmendedAndRestaredOne	0.63
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31524794	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.86
CY2020Q1	tenx	Unregistered Warrants To Purchase UnregisteredWarrantsToPurchase	2360313	shares
CY2020Q1	tenx	Exercise Price Per Unit ExercisePricePerUnit	1.04
	tenx	Shares Available For Grant SharesAvailableForGrant	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares Available for Grant</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balances, at December 31, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares reserved under 2022 Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,100,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shares rolled over from 2016 Plan</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">819,750</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options granted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(571,250</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options cancelled/forfeited </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">195,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balances, at September 30, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,543,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
	tenx	Stock Activity Plan StockActivityPlan	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balances at December 31, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">663,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.90</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options cancelled/forfeited </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(195,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.62</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balances at September 30, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">468,250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.02</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
	tenx	Schedule Of Stock Option Plan ScheduleOfStockOptionPlan	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Outstanding Options</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Number of Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Weighted Average Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balances at December 31, 2021</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,317</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">42.26</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Options cancelled/forfeited </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(17,597</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">28.00</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Balances at September 30, 2022</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18,720</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">55.66</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q3	tenx	Issuance Of Pre Fund Warrant IssuanceOfPreFundWarrant	14716032	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0001

Files In Submission

Name	View Source	Status
0001654954-22-015030-index-headers.html	Edgar Link	pending
0001654954-22-015030-index.html	Edgar Link	pending
0001654954-22-015030.txt	Edgar Link	pending
0001654954-22-015030-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tenx-20220930.xsd	Edgar Link	pending
tenx_10q.htm	Edgar Link	pending
tenx_ex311.htm	Edgar Link	pending
tenx_ex312.htm	Edgar Link	pending
tenx_ex321.htm	Edgar Link	pending
tenx_ex322.htm	Edgar Link	pending
tenx-20220930_def.xml	Edgar Link	unprocessable
tenx-20220930_pre.xml	Edgar Link	unprocessable
tenx-20220930_lab.xml	Edgar Link	unprocessable
tenx_10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
tenx-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TENX
TENAX THERAPEUTICS, INC. Stock $tenx

2022 Q4 Form 10-Q Financial Statement

#000165495422015030 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TENX TENAX THERAPEUTICS, INC. Stock $tenx

2022 Q4 Form 10-Q Financial Statement

#000165495422015030 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TENX
TENAX THERAPEUTICS, INC. Stock $tenx